MOHLTC - Health care Providers - Ontario Public Drug Programs

Public Information

Health Care Providers

Plan to Reform Ontario's Drug System

Legislation

Formulary

· About the Formulary
· Formulary Edition 40 and 41
Downloads
· Search e-Formulary
· Formulary Resources
· Drug Benefit Prices
  for products reimbursed
  under the EAP
· Conditions for Payment
  of Dispensing Fee
  – Exempted Products List

Exceptional Access Program

Publicly Funded Drug Programs

Executive Officer Communications

Drug Submissions

How Drugs Are Approved

MedsCheck

FAQs

Formulary

Exceptional Access Program (EAP)

The Individual Clinical Review process is being phased out and a more streamlined Exceptional Access Program (EAP) has been created to handle requests for drugs that are not listed in the Formulary. For more information please visit the EAP section.

Drug Benefit Prices (DBPs) for products reimbursed under the EAP

Pursuant to section 15 of O.Reg. 201/96 made under the Ontario Drug Benefit Act (ODBA), the Executive Officer (EO) has entered into agreements with manufacturers to establish Drug Benefit Prices (DBPs) for products reimbursed under the Exceptional Access Program (EAP).

For the following products reimbursed under the EAP, the Health Network System (HNS) will adjudicate claims at the DBP listed below.

DIN	Trade Name	Strength	Dosage Form	DBP
Effective date : October 8, 2009
02169649	Betaseron	0.3mg/Vial	Injection	$110.0000
Effective date : September 21, 2009
02286386	Tysabri	300mg/15mL vial	Inj Sol-15mL Vial Pk	$2,809.1900
Effective date : July 22, 2009
02317699	Revlimid	15mg	Cap	$382.0000
02317710	Revlimid	25mg	Cap	$424.0000
Effective date : June 11, 2009
02284863	Myozyme	50mg/vial	Lyophylized Powder	$840.3100
Effective date : June 1, 2009
02241112	Avandia	2mg	Tab	$1.3755
02241113	Avandia	4mg	Tab	$2.1584
02241114	Avandia	8mg	Tab	$3.0866
Effective date : May 27, 2009
02296314	Elaprase	2mg/mL	3mL Vial	$3,800.00
Effective date : May 20, 2009
02258595	Humira	40mg/0.8mL	Inj Pref Syr	$707.2200
09857294	Humira	40mg/0.8mL	Inj Pref Pen	$707.2200
Effective Date : April 29, 2009
02287420	Exjade	125mg	Tablet for Suspension	$9.8750
02287439	Exjade	250mg	Tablet for Suspension	$19.7500
02287447	Exjade	500mg	Tablet for Suspension	$39.5000
Effective Date : January 19, 2009
02304899	Revlimid	5mg	Capsule	$340.0000
02304902	Revlimid	10mg	Capsule	$361.0000
Effective Date : December 3, 2008
2274728	Enbrel	50mg/mL	Inj Pref Syr	$364.2800
Effective Date : November 17, 2008
02284227	Nexavar	200mg	Tablet	$45.0625
Effective Date : October 31, 2008
02282097	Orencia	250mg/15mL Vial	Injection	$440.0000
Effective Date : May 30, 2008
02280795	Sutent	12.5mg	Capsule	$62.0357
02280809	Sutent	25mg	Capsule	$124.0711
02280817	Sutent	50mg	Capsule	$248.1425

Until further notice, for all other products reimbursed under the EAP, pharmacists will continue to be reimbursed their acquisition cost plus the applicable markup (currently 8%).



INFOline Tel : 1-866-532-3161 (Toll-free in Ontario only) TTY 1-800-387-5559 Hours of operation: 8:30am - 5:00pm